The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.

"Declarations Ethical approvalAll patients provided written informed consent. All procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Both trials were performed in accordance with local regulations and approved by the responsible ethics committees (Ethikkommission der Medizinischen Fakultät Göttingen (GLSG1996); Ethikkommission der Medizinischen Fakultät der LMU (GLSG2000). The trials were started before preregistration was implemented and are therefore not registered. Conflict of interestBittenbring JT received travel support and honoraria from Gilead, Incyte and MDS.Hübel K served as an advisor and consultant for Roche, Celgene/BMS, Gilead, Incyte, EUSA, Novartis, received honoraria from Roche, Celgene/BMS, Servier, EUSA, BeiGene, Novartis and research support from Roche, Alexion, Celgene/BMS, Janssen, Incyte.Schmidt C served as a consultant for Novartis, Kite/Gilead, Takeda, BMS, received honoraria from Novartis, Kite/Gilead, travel support from Novartis, Kite/Gilead, Takeda, BMS, Janssen and research funding from Kite/Gilead.Glaß B served as a consultant for BMS, Roche, Riemser, Kite, Novartis, served in the speakers bureau of Roche and received research funding from Roche and Riemser.Hüttmann A received honoraria from Celgene, Gilead, Takeda, served as a consultant for Lead Discovery Center GmbH and is a member of a Board or Advisory Committee for Takeda.Hiddemann W received research support from Roche.Unterhalt M received research support from Roche.Dreyling M received speaker’s honoraria from Amgen, Astra Zeneca, Bayer, BMS/Celgene, Gilead/Kite, Incyte, Janssen, Novartis, Roche, served on scientific advisory bords for Astra Zeneca, Bayer, Beigene, BMS/Celgene, Genmab, Gilead/Kite, Incyte, Janssen, Lilly/Loxo, Morphosys, Novartis, Roche and received research support from Abbvie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Roche.All remaining authors have declared no conflicts of interest. Conflict of interest Bittenbring JT received travel support and honoraria from Gilead, Incyte and MDS. Hübel K served as an advisor and consultant for Roche, Celgene/BMS, Gilead, Incyte, EUSA, Novartis, received honoraria from Roche, Celgene/BMS, Servier, EUSA, BeiGene, Novartis and research support from Roche, Alexion, Celgene/BMS, Janssen, Incyte. Schmidt C served as a consultant for Novartis, Kite/Gilead, Takeda, BMS, received honoraria from Novartis, Kite/Gilead, travel support from Novartis, Kite/Gilead, Takeda, BMS, Janssen and research funding from Kite/Gilead. Glaß B served as a consultant for BMS, Roche, Riemser, Kite, Novartis, served in the speakers bureau of Roche and received research funding from Roche and Riemser. Hüttmann A received honoraria from Celgene, Gilead, Takeda, served as a consultant for Lead Discovery Center GmbH and is a member of a Board or Advisory Committee for Takeda. Hiddemann W received research support from Roche. Unterhalt M received research support from Roche. Dreyling M received speaker’s honoraria from Amgen, Astra Zeneca, Bayer, BMS/Celgene, Gilead/Kite, Incyte, Janssen, Novartis, Roche, served on scientific advisory bords for Astra Zeneca, Bayer, Beigene, BMS/Celgene, Genmab, Gilead/Kite, Incyte, Janssen, Lilly/Loxo, Morphosys, Novartis, Roche and received research support from Abbvie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Roche. All remaining authors have declared no conflicts of interest."

"Funding Open Access funding enabled and organized by Projekt DEAL."